Compare Ryanair Holdings plc (RYAAY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ryanair Holdings plc vs TG Therapeutics Inc — how do they compare? Ryanair Holdings plc trades at $54.39 (market cap $27.11B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: Ryanair Holdings plc is far larger — about 3.3× TG Therapeutics Inc's market cap, and Ryanair Holdings plc pays a 1.66% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ryanair Holdings plc for 72 Days and TG Therapeutics Inc for 16 Days on average.
| RYAAY | TGTX | |
|---|---|---|
Market Cap | $27.11B | $8.16B |
Volume | 2,427,380 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $73.82 | $59.06 |
52-Week Low | $51.95 | $26.94 |
Typical Hold Time | 72 Days | 16 Days |
Enterprise Value | $24.18B | $8.37B |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RYAAY trades at $54.24, down 3.14% on the day, with a bearish technical signal from moving averages. The stock shows solid fundamentals with a P/E of 13.43 and net income margin of 12.13%, but recent earnings have missed expectations. Cash flow turned negative in 2025, and the company faces headwinds from high fuel costs and Boeing MAX 10 certification delays, as reported by Reuters on September 29, 2026.
The outlook is mixed: valuation appears attractive, and analyst consensus is moderately bullish with 64.71% buy ratings, but near-term risks from oil price volatility and operational challenges pressure the stock. Investors should weigh strong profitability and market position against earnings volatility and external uncertainties.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
